ST Germain D J Co. Inc. Buys 10,279 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

ST Germain D J Co. Inc. increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2,712.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,658 shares of the medical research company’s stock after buying an additional 10,279 shares during the quarter. ST Germain D J Co. Inc.’s holdings in Thermo Fisher Scientific were worth $6,195,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of TMO. Kestra Advisory Services LLC grew its holdings in shares of Thermo Fisher Scientific by 15.7% in the third quarter. Kestra Advisory Services LLC now owns 27,014 shares of the medical research company’s stock valued at $13,674,000 after acquiring an additional 3,666 shares in the last quarter. QRG Capital Management Inc. purchased a new position in shares of Thermo Fisher Scientific in the 3rd quarter worth about $12,894,000. Envestnet Portfolio Solutions Inc. purchased a new stake in Thermo Fisher Scientific during the third quarter worth about $18,442,000. Envestnet Asset Management Inc. boosted its stake in Thermo Fisher Scientific by 21.9% in the third quarter. Envestnet Asset Management Inc. now owns 698,445 shares of the medical research company’s stock valued at $353,532,000 after acquiring an additional 125,267 shares during the last quarter. Finally, TRUE Private Wealth Advisors grew its position in shares of Thermo Fisher Scientific by 10.3% during the 3rd quarter. TRUE Private Wealth Advisors now owns 1,202 shares of the medical research company’s stock valued at $608,000 after acquiring an additional 112 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have weighed in on TMO. Barclays increased their price objective on Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a report on Thursday, April 25th. Robert W. Baird dropped their price objective on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, April 25th. HSBC boosted their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. Deutsche Bank Aktiengesellschaft lifted their target price on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a report on Thursday, April 25th. Finally, JPMorgan Chase & Co. upped their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $607.94.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $567.28, for a total value of $5,672,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $70,238,340.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at $70,238,340.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the sale, the senior vice president now owns 13,083 shares of the company’s stock, valued at $7,430,359.02. The disclosure for this sale can be found here. Insiders sold 22,000 shares of company stock worth $12,532,780 over the last quarter. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Up 0.2 %

TMO traded up $1.17 during midday trading on Tuesday, reaching $569.17. The company’s stock had a trading volume of 1,398,060 shares, compared to its average volume of 1,486,346. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. The stock’s 50-day moving average is $574.95 and its 200-day moving average is $559.33. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The firm has a market capitalization of $217.26 billion, a price-to-earnings ratio of 36.43, a PEG ratio of 2.67 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating the consensus estimate of $4.70 by $0.41. The company had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Friday, June 14th will be issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date of this dividend is Friday, June 14th. Thermo Fisher Scientific’s payout ratio is 10.01%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.